-
Rising Kenyan lakes push crocodiles closer to homes
-
Pacific islands alarmed by Trump-backed push for deep-sea mining
-
Istanbul cymbals: From Ottoman war tool to pulse of global music
-
Erratic rains dictate menu at three-star Michelin restaurant in Brazil
-
Myanmar ex-junta chief on first Thailand trip as civilian leader
-
Zverev, Auger-Aliassime and Medvedev exit Montreal Masters
-
Environmental disaster looms as tanker leaks off Oman
-
Google-parent Alphabet shakes up AI division
-
Embattled Infantino sees minnows Malawi reach WAFCON quarter-finals
-
FIFA back Infantino, apologise for World Cup privatisation plan
-
Seeds Rybakina, Pegula and Gauff advance at WTA Toronto event
-
Auger-Aliassime out of Montreal ATP event with injury
-
Zverev, Auger-Aliassime exit star-short Montreal Masters
-
Colombian baby hippo of Escobar stock dies after rescue
-
Embattled FIFA chief Infantino in emergency talks in Morocco
-
Preakness shifts 2027 dates to entice more Derby horses
-
Castaway SpaceX rocket stage crashed into Moon, scientists say
-
Guatemalan volcano eruption ends, locals return home
-
Dow edges to record as markets parse prospects for Hormuz deal
-
WHO chief urges stronger Ebola response in DR Congo visit
-
Salah arrives in Turkey to complete Trabzonspor move
-
Newcastle appoint Jaissle as new head coach after Howe exit
-
AFP journalist to be honored at International Press Freedom Awards
-
Swiss ski star Lara Gut-Behrami calls time on 18-year career
-
Turkish MPs back limited amnesty for Kurdish militants
-
US indicts leaders of Mexico's CJNG cartel, ups reward money
-
Noosha Aubel: Czy poradzi sobie z problemami Poczdamu?
-
Noosha Aubel: Klarar hon av Potsdams problem?
-
Noosha Aubel: Είναι σε θέση να αντιμετωπίσει τα προβλήματα του Πότσδαμ;
-
Noosha Aubel: Zvládne problémy Postupimi?
-
نوشا أوبيل: هل هي على مستوى التحديات التي تواجهها بوتسدام؟
-
Former England fly-half Burns retires from rugby union
-
Brazil hits new diplomatic lows with US and Argentina
-
Pakistan beat West Indies by eight wickets to level series
-
NZ boxer Parker promises ring return after doping ban 'lifted'
-
Reusser holds lead as Vollering wins in Tour de France hills
-
Disney profits top estimates on strength in theme park business
-
Argentina's Albornoz hit with four-game ban for 'intimidatory' referee abuse
-
LIV Golf CEO says funding secured to play beyond 2026
-
Guatemala volcano eruption eases off, but alert remains in place
-
Stocks stall tracking earnings, oil dips on Iran-Oman Hormuz move
-
Baby hippo descended from Escobar's herd rescued in Colombia
-
Tuipulotu to lead New Zealand in South African tour opener
-
Woman arrested after four men stabbed in central London
-
Leftist Democrat urges unity after victory in Michigan
-
Celtic boss O'Neill in hospital after 'small procedure'
-
Austria, Slovakia hit new temperature records
-
Israeli forces raid Palestinian refugee camp near Jerusalem
-
Where mountain lions roam, fewer deer in the headlights
-
Explosive drone found near Ukrainian plane at German airport
US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
R.Veloso--PC